The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease
It is widely accepted that the endocrine hormone leptin controls food intake and energy homeostasis via activation of leptin receptors expressed on hypothalamic arcuate neurons. The hippocampal formation also displays raised levels of leptin receptor expression and accumulating evidence indicates th...
Saved in:
Main Authors: | , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_3d7de7ffd6cc4e788a1fc6772e06a3b9 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Kirsty Hamilton |e author |
700 | 1 | 0 | |a Jenni Harvey |e author |
245 | 0 | 0 | |a The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease |
260 | |b MDPI AG, |c 2021-01-01T00:00:00Z. | ||
500 | |a 10.3390/ph14010052 | ||
500 | |a 1424-8247 | ||
520 | |a It is widely accepted that the endocrine hormone leptin controls food intake and energy homeostasis via activation of leptin receptors expressed on hypothalamic arcuate neurons. The hippocampal formation also displays raised levels of leptin receptor expression and accumulating evidence indicates that leptin has a significant impact on hippocampal synaptic function. Thus, cellular and behavioural studies support a cognitive enhancing role for leptin as excitatory synaptic transmission, synaptic plasticity and glutamate receptor trafficking at hippocampal Schaffer collateral (SC)-CA1 synapses are regulated by leptin, and treatment with leptin enhances performance in hippocampus-dependent memory tasks. Recent studies indicate that hippocampal temporoammonic (TA)-CA1 synapses are also a key target for leptin. The ability of leptin to regulate TA-CA1 synapses has important functional consequences as TA-CA1 synapses are implicated in spatial and episodic memory processes. Moreover, degeneration is initiated in the TA pathway at very early stages of Alzheimer's disease, and recent clinical evidence has revealed links between plasma leptin levels and the incidence of Alzheimer's disease (AD). Additionally, accumulating evidence indicates that leptin has neuroprotective actions in various AD models, whereas dysfunctions in the leptin system accelerate AD pathogenesis. Here, we review the data implicating the leptin system as a potential novel target for AD, and the evidence that boosting the hippocampal actions of leptin may be beneficial. | ||
546 | |a EN | ||
690 | |a Leptin | ||
690 | |a hippocampus | ||
690 | |a synaptic plasticity | ||
690 | |a tau | ||
690 | |a AMPA | ||
690 | |a Alzheimer's | ||
690 | |a Medicine | ||
690 | |a R | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceuticals, Vol 14, Iss 1, p 52 (2021) | |
787 | 0 | |n https://www.mdpi.com/1424-8247/14/1/52 | |
787 | 0 | |n https://doaj.org/toc/1424-8247 | |
856 | 4 | 1 | |u https://doaj.org/article/3d7de7ffd6cc4e788a1fc6772e06a3b9 |z Connect to this object online. |